Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis
Authors:
- 11 August 2015
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 18 (3) , 322-330
Abstract
Objective Metastatic breast cancer (MBC) remains the main cause of cancer-related death, and the clinical significance and prognostic role of circulating tumor cells (CTCs) in metastatic breast cancer are still controversial. Here, we conducted a meta-analysis to clarify the correlation between CTCs and the clinicopathological features and prognosis of MBC. Methods We performed a comprehensive search of Pubmed and the ISI Web of Science through December 2014. Only articles that focused on MBC patients and detected CTCs using the CellSearch system were included. The associations between CTCs and survival rate and clinicopathological parameters, including molecular pattern, metastatic region and treatment response, were evaluated. Results This meta-analysis included 24 studies (3701 MBC patients), 13 prospective studies and 11 retrospective studies. We found that CTCs were more frequently detected with HER2 + primary tumors (pooled RR = 0.73, 95 % CI = 0.63–0.84). Additionally, higher CTC numbers indicated a worse treatment response (RR = 0.56, 95 % CI = 0.40–0.79), poorer PFS (RR = 0.64, 95 % CI = 0.56–0.73) and poorer OS (RR = 0.69, 95 % CI = 0.64–0.75) in MBC patients. Conclusion Based on these results, we propose that HER2 positivity could be a significant risk factor for the presence of CTCs. Additionally, CTCs have a significant prognostic value for MBC patients. Therefore, CTCs should be continually monitored to guide the treatment of MBC patients, especially those with HER2 + primary tumors.Keywords
Funding Information
- Science and Technology Department of Zhejiang Province (LY15H160053)
This publication has 39 references indexed in Scilit:
- Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarkerBMC Cancer, 2013
- The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast CancerClinical Breast Cancer, 2012
- Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodiesBMC Cancer, 2012
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyAnnals of Oncology, 2011
- High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patientsAnnals of Oncology, 2011
- The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancerBreast Cancer Research and Treatment, 2011
- Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate CancerJournal of Oncology, 2009
- Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cellsAnnals of Oncology, 2008
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall SurvivalClinical Cancer Research, 2006